After buying a portion of IFM Therapeutics’ pipeline in 2019, Novartis is back for a second helping as it bags its STING antagonists.
The Swiss Big Pharma had paid $90 million upfront a few years ago for an option and collaboration agreement and would pay up to $745 million in milestones if it opted to acquire IFM’s subsidiary IFM Due.
Its time is due, and the companies said Wednesday that Novartis will have full rights to IFM Due’s portfolio of STING antagonists, which could turn into treatments for inflammation-driven diseases. The deal is a result of a four-year preclinical tie-up on small molecules.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.